SCHEMBL696562

SCHEMBL696562

FC(F)(F)N1CCCCC1

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CYP2B6 P20813 1/20 0.32
MGLL Q99685 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5390320 1.00 CYP2B6 (0.32) CYP2B6MGLL
Ammonia Solution, Strong SCHEMBL31168140 0.97 CYP2B6 (0.31) CYP2B6
Hydrochloric Acid SCHEMBL9035395 0.97 CYP2B6 (0.31) CYP2B6
Hydrochloric Acid SCHEMBL1507301 0.97 CYP2B6 (0.31) CYP2B6
Bromide SCHEMBL29204968 0.97 CYP2B6 (0.31) CYP2B6
SCHEMBL7048888 0.96
SCHEMBL518019 0.96
Hydrochloric Acid SCHEMBL16238627 0.93
SCHEMBL3505975 0.89
SCHEMBL10006193 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12502386-B2 Nitrogen-containing heterocyclic compound and use thereof Shanghai Shijiang Biotechnology Co., Ltd. (CN) 2025-12-23 US claimed
US-20250197389-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND SHANGHAI SHIJIANG BIOTECHNOLOGY CO., LTD (CN) 2025-06-19 US claimed
US-20250197415-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF SHANGHAI SHIJIANG BIOTECHNOLOGY CO., LTD (CN) 2025-06-19 US claimed
CN-114430064-B In-situ preparation and application of polymer solid electrolyte 深圳先进技术研究院 2024-09-20 CN claimed
CN-118580470-A Cationic polymer based on halogenated m-terphenyl group, and preparation method and application thereof 西湖大学 2024-09-03 CN claimed
CN-117728010-A Solid electrolyte material, preparation method and solid battery 蜂巢能源科技(无锡)有限公司 2024-03-19 CN claimed
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof NOVARTIS AG (CH) 2023-10-17 US claimed
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof NOVARTIS AG (CH) 2023-04-06 US claimed
US-10221172-B2 Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction VANDERBILT UNIVERSITY (US) 2019-03-05 US claimed
US-20180022744-A1 BENZOTHIAZOLE AND BENZISOTHIAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION VANDERBILT UNIVERSITY 2018-01-25 US claimed
WO-1997042155-A1 ANTI-VIRAL COMPOUNDS ELI LILLY AND COMPANY (US) 1997-11-13 WO claimed
WO-1997041849-A1 ANTI-VIRAL METHOD ELI LILLY AND COMPANY (US) 1997-11-13 WO claimed
WO-1997042156-A1 ANTI-VIRAL COMPOUNDS ELI LILLY AND COMPANY (US) 1997-11-13 WO claimed
WO-1997041822-A2 ANTI-VIRAL COMPOUNDS ELI LILLY AND COMPANY (US) 1997-11-13 WO claimed
EP-0806203-A2 Anti-viral compositions ELI LILLY AND COMPANY (US) 1997-11-12 EP claimed
EP-0806411-A2 Anti-viral compounds ELI LILLY AND COMPANY (US) 1997-11-12 EP claimed
EP-0806409-A1 Anti-viral compounds ELI LILLY AND COMPANY (US) 1997-11-12 EP claimed
EP-0806410-A2 Anti-viral compounds ELI LILLY AND COMPANY (US) 1997-11-12 EP claimed
EP-0806408-A1 Anti-viral compounds ELI LILLY AND COMPANY (US) 1997-11-12 EP claimed
EP-0764641-A1 NOVEL 4,5-DISUBSTITUTED PYRIMIDINE DERIVATIVE AND HERBICIDE NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1997-03-26 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787785-B2 Pyrazolopyridine derivatives and uses thereof HBZ, ZFX, WIZ CYP2B6 2986/4885MGLL 4859/4885
US-20250197389-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND PPIF, PIN1, NME4 CYP2B6 1755/4885MGLL 4575/4885
US-20180022744-A1 BENZOTHIAZOLE AND BENZISOTHIAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION GRM4, GRIK4, GRIA4 CYP2B6 3223/4885MGLL 3293/4885
US-10221172-B2 Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction GRM4, GRIK4, GRIA4 CYP2B6 3223/4885MGLL 3293/4885
US-20230108325-A1 Pyrazolopyridine Derivatives and Uses thereof HBZ, ZFX, WIZ CYP2B6 2986/4885MGLL 4859/4885
US-20250197415-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF UHRF1, NNMT, EHMT1 CYP2B6 2003/4885MGLL 4862/4885
US-12502386-B2 Nitrogen-containing heterocyclic compound and use thereof UHRF1, NNMT, EHMT1 CYP2B6 2003/4885MGLL 4862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.